Figure 4: Guanabenz treatment delays and alleviates clinical symptoms in mice with chronic EAE. | Nature Communications

Figure 4: Guanabenz treatment delays and alleviates clinical symptoms in mice with chronic EAE.

From: Pharmaceutical integrated stress response enhancement protects oligodendrocytes and provides a potential multiple sclerosis therapeutic

Figure 4

(a) Clinical scores of wild type C57BL/6J female mice immunized with CFA and MOG35–55 to induce chronic EAE, treated with vehicle (n=15) or 4 mg kg−1 (n=15), 8 mg kg−1 (n=15) or 16 mg kg−1 (n=14) guanabenz daily from PID7 to the end of the study. (b–d) Average onset of disease, defined as the day a clinical score of 1.0 was first reached in each mouse (b), peak of disease (c) and incidence of disease (d) of all treatment groups. Data in (a–d) represent one of two studies conducted with similar results and presented as mean±s.e.m. Unpaired t-test, *P<0.05, ***P<0.0005 compared with vehicle.

Back to article page